BioSpace News Archive

Apnimed, Inc. announced a new joint venture with Shionogi & Co., Ltd., a leading global research-driven pharmaceutical company based in Japan, to develop novel pharmacologic therapies to treat obstructive sleep apnea and other sleep disorders.

OKYO Pharma Limited announced a $5.84M issuance of shares via: a Company managed registered direct offering of 1,092,600 ordinary shares at an offering price of $1.50 per ordinary share conducted without an underwriter or placement agent; and the extinguishment of payables of $4.20M by the issuance of 2,766,667 shares at the offering price of $1.50 per share.

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of CHM 2101, Chimeric’s first in class CDH17 CAR T cell therapy for gastrointestinal cancers.

XOMA Corporation, the biotech royalty aggregator, announced it has earned a $5 million milestone related to the U.S. Food and Drug Administration’s acceptance of Day One Biopharmaceuticals’ New Drug Application for tovorafenib as a monotherapy for relapsed or progressive pediatric low-grade glioma.

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported third quarter 2023 financial results and recent portfolio execution.

HuidaGene Therapeutics announced the first patient has been dosed in the multinational, master-protocol Phase 1/2a clinical trial of HG004 gene therapy drug, or the STAR study, an adeno-associated virus 9 gene replacement therapy candidate for the treatment of inherited retinal dystrophies caused by RPE65 mutations.

Accuray Incorporated announced its participation in the 14th Annual Jefferies London Healthcare Conference.

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”) today announced Phase 2 interim results for CYB003, its proprietary deuterated psilocybin analog, demonstrating a rapid, robust and statistically significant reduction in symptoms of depression three weeks following a single 12mg dose compared to placebo.

MBX Biosciences, Inc. announced that Kent Hawryluk, President and Chief Executive Officer, will present at the Stifel 2023 Healthcare Conference on Tuesday, November 14th, 2023, at 2:25 p.m. Eastern Time and will host 1-on-1 investor meetings.

Alimera Sciences, Inc. announces that clinical data for ILUVIEN® 0.19 mg taken from the three-year, phase IV, real-world observational PALADIN study evaluating the long-term safety of ILUVIEN for patients with diabetic macular edema, will be featured in three posters and a presentation on behalf of the PALADIN Investigators, during the American Academy of Ophthalmology’s 127th Annual Meeting being held in San Francisco from November 3-6, 2023.